The IASLC 2025 Targeted Therapies of Lung Cancer Meeting, February 19-22, 2025, is a dynamic event with a long tradition. Meeting presenters will summarize data on relevant targets for new therapies and share data on preclinical and early clinical trials for each of the drugs directed against these targets.

The Targeted Therapies of Lung Cancer meeting is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer and other thoracic malignancies, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, physician assistants and nurses.

Upon completion of this activity, the participants should be able to: 

• Understand data on relevant targets for new therapies.
• Understand data on preclinical and early clinical trials for each of the drugs directed against relevant targets.

• Charu Aggarwal, MD, University of Pennsylvania
• Paul A. Bunn, Jr., MD, University of Colorado Anschutz Medical Center
• Joel Neal, MD, PhD, Stanford University Medical Center
• Karen Reckamp, MD, MS, Cedars-Sinai Medical Center

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

For assistance with this activity, please email: education@iaslc.org.